stockrow
Friday 6 November 2026
Export NCEL’s income statement to Excel — free account
NewcelX Ltd.
NCEL Healthcare Biotechnology
2.72
0.17
−5.88%
Follow NCEL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (5) | (5) | (3) | (12) | (16) | (12) | (7) | (8) | (31) | +7.1% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (5) | (5) | (3) | (12) | (16) | (12) | (7) | (8) | (11) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.46) | (318.55) | (164.00) | (400.00) | (336.00) | (128.00) | (2.43) | (2.16) | (1.53) | +24.7% | ||||||
| Cash flow | — | — | (0.25) | (11.11) | (41.92) | (501.21) | (282.10) | (101.51) | (0.36) | (0.72) | 0.00 | +16.6% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (1.33) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.25) | (11.11) | (41.92) | (502.54) | (282.10) | (101.51) | (0.36) | (0.72) | 0.00 | +16.7% | ||||||
| Book value | — | — | (0.79) | (360.88) | (516.33) | 18.20 | 66.68 | (92.60) | (2.70) | 1.89 | 0.00 | n/m | ||||||
| Shares, m | — | — | 11 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | — | (14.1%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | 0 | (1) | (15) | (14) | (10) | (1) | (3) | (5) | +0.2% | |||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | 0 | 0 | (33.0%) | ||||||
| Free cash flow | — | — | (3) | 0 | (1) | (15) | (14) | (10) | (1) | (3) | (5) | +0.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (2) | (4) | (7) | 3 | 6 | (6) | (8) | (1) | (2) | (11.2%) | |||||
| Net debt | — | — | 7 | 0 | 1 | (5) | (9) | 1 | 7 | (2) | 0 | n/m | ||||||
| Shareholders’ equity | — | — | (9) | (6) | (9) | 1 | 3 | (9) | (8) | 7 | 6 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (7,069.78) | (1,293.85) | (299.94) | (342.48) | (219.34) | (218.86) | (523.49) | (134.43) | 0.00 | +6,935.3 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (29.63) | 0.00 | (29.6) pt | ||||||
| ROE | — | — | 68.69 | 72.70 | 37.76 | 283.03 | (862.93) | 438.41 | 85.53 | 2,225.20 | 0.00 | +2,156.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 4 | 6 | 6 | 2 | 4 | 3 | 4 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
NewcelX Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| Median of peers | $15.4M | — | — | −75.61% | — | +21.02% | 62.79% | 0.00% |